相似文献
1
In vitro activity of anidulafungin against selected clinically important mold isolates.
Antimicrob Agents Chemother. 2004 May;48(5):1912-5. doi: 10.1128/AAC.48.5.1912-1915.2004.
2
In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.
Antimicrob Agents Chemother. 2005 Aug;49(8):3572-4. doi: 10.1128/AAC.49.8.3572-3574.2005.
3
In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.
J Antimicrob Chemother. 1998 Dec;42(6):741-5. doi: 10.1093/jac/42.6.741.
4
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Diagn Microbiol Infect Dis. 2003 Feb;45(2):131-5. doi: 10.1016/s0732-8893(02)00507-2.
5
Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
J Clin Microbiol. 1998 Oct;36(10):2950-6. doi: 10.1128/JCM.36.10.2950-2956.1998.
6
In vitro activities of eight antifungal drugs against 55 clinical isolates of Fonsecaea spp.
Antimicrob Agents Chemother. 2010 Apr;54(4):1636-8. doi: 10.1128/AAC.01655-09. Epub 2010 Jan 19.
7
Antifungal susceptibilities of the species of the Pseudallescheria boydii complex.
Antimicrob Agents Chemother. 2006 Dec;50(12):4211-3. doi: 10.1128/AAC.00981-06. Epub 2006 Oct 2.
8
In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi.
Med Mycol. 2005 May;43(3):281-4. doi: 10.1080/13693780500088416.
9
In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens.
Antimicrob Agents Chemother. 1997 Apr;41(4):841-3. doi: 10.1128/AAC.41.4.841.
10
In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients.
J Antimicrob Chemother. 1999 Nov;44(5):697-700. doi: 10.1093/jac/44.5.697.
引用本文的文献
1
Invasive fungal infections and oomycoses in cats 2. Antifungal therapy.
J Feline Med Surg. 2024 Jan;26(1):1098612X231220047. doi: 10.1177/1098612X231220047.
2
The delayed clearance of Talaromyces marneffei in blood culture may be associated with higher MIC of voriconazole after antifungal therapy among AIDS patients with talaromycosis.
PLoS Negl Trop Dis. 2023 Apr 3;17(4):e0011201. doi: 10.1371/journal.pntd.0011201. eCollection 2023 Apr.
3
Exophiala dermatitidis Central Line-Associated Bloodstream Infection in a Child with Ewing's Sarcoma: Case Report and Literature Review on Paediatric Infections.
Mycopathologia. 2022 Dec;187(5-6):595-602. doi: 10.1007/s11046-022-00658-1. Epub 2022 Aug 22.
4
Cutaneous Phaeohyphomycosis of the Right Hand Caused by Exophiala jeanselmei: A Case Report and Literature Review.
Mycopathologia. 2022 Jun;187(2-3):259-269. doi: 10.1007/s11046-022-00623-y. Epub 2022 Mar 21.
5
Echinocandins - structure, mechanism of action and use in antifungal therapy.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):876-894. doi: 10.1080/14756366.2022.2050224.
6
Comparative Analysis of Different Isolated Oleaginous Mucoromycota Fungi for Their -Linolenic Acid and Carotenoid Production.
Biomed Res Int. 2020 Nov 5;2020:3621543. doi: 10.1155/2020/3621543. eCollection 2020.
7
Community-acquired Disseminated Exophiala dermatitidis Mycosis with Necrotizing Fasciitis in Chronic Graft-versus-host Disease.
Intern Med. 2019 Mar 15;58(6):877-882. doi: 10.2169/internalmedicine.1706-18. Epub 2018 Nov 19.
8
Susceptibility profile of echinocandins, azoles and amphotericin B against yeast phase of Talaromyces marneffei isolated from HIV-infected patients in Guangdong, China.
Eur J Clin Microbiol Infect Dis. 2018 Jun;37(6):1099-1102. doi: 10.1007/s10096-018-3222-x. Epub 2018 Mar 13.
9
Activity of Posaconazole against Talaromyces marneffei by Broth Microdilution and Etest Methods and Comparison to Itraconazole, Voriconazole, and Anidulafungin.
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.01480-16. Print 2017 Mar.
10
Mycetoma medical therapy.
PLoS Negl Trop Dis. 2014 Oct 16;8(10):e3218. doi: 10.1371/journal.pntd.0003218. eCollection 2014 Oct.
本文引用的文献
1
Successful voriconazole therapy of disseminated Fusarium solani in the brain of a neutropenic cancer patient.
Cancer Control. 2003 Sep-Oct;10(5):414-9. doi: 10.1177/107327480301000511.
2
Successful treatment of Scedosporium pneumonia with voriconazole during AML therapy and bone marrow transplantation.
Med Pediatr Oncol. 2003 Nov;41(5):494-5. doi: 10.1002/mpo.10363.
3
Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis.
Drugs. 2003;63(20):2235-63. doi: 10.2165/00003495-200363200-00008.
4
Successsful voriconazole treatment of disseminated fusarium infection in an immunocompromised patient.
Clin Infect Dis. 2003 Jul 15;37(2):311-3. doi: 10.1086/375842. Epub 2003 Jul 9.
5
Voriconazole in the treatment of invasive mold infections in transplant recipients.
Eur J Clin Microbiol Infect Dis. 2003 Jul;22(7):408-13. doi: 10.1007/s10096-003-0960-0. Epub 2003 Jun 24.
6
Antifungal agents: mechanisms of action.
Trends Microbiol. 2003 Jun;11(6):272-9. doi: 10.1016/s0966-842x(03)00117-3.
7
Caspofungin.
Clin Infect Dis. 2003 Jun 1;36(11):1445-57. doi: 10.1086/375080. Epub 2003 May 19.
8
In vitro activity of voriconazole, itraconazole, caspofungin, anidulafungin (VER002, LY303366) and amphotericin B against aspergillus spp.
Diagn Microbiol Infect Dis. 2003 Feb;45(2):131-5. doi: 10.1016/s0732-8893(02)00507-2.
9
Emerging and less common fungal pathogens.
Infect Dis Clin North Am. 2002 Dec;16(4):915-33, vi-vii. doi: 10.1016/s0891-5520(02)00041-7.
10
Caspofungin acetate for treatment of invasive fungal infections.
Ann Pharmacother. 2003 Jan;37(1):90-8. doi: 10.1345/aph.1C114.
Zotero 插件